AU2002218002A1 - Use of pyridoxamine for the treatment and inhibition of obesity-related complications - Google Patents

Use of pyridoxamine for the treatment and inhibition of obesity-related complications

Info

Publication number
AU2002218002A1
AU2002218002A1 AU2002218002A AU1800202A AU2002218002A1 AU 2002218002 A1 AU2002218002 A1 AU 2002218002A1 AU 2002218002 A AU2002218002 A AU 2002218002A AU 1800202 A AU1800202 A AU 1800202A AU 2002218002 A1 AU2002218002 A1 AU 2002218002A1
Authority
AU
Australia
Prior art keywords
obesity
related complications
pyridoxamine
inhibition
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002218002A
Inventor
John Baynes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Carolina
Original Assignee
University of South Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Carolina filed Critical University of South Carolina
Publication of AU2002218002A1 publication Critical patent/AU2002218002A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • External Artificial Organs (AREA)

Abstract

The present invention provides methods and pharmaceutical compositions for treating or inhibiting obesity-related complications that comprise administering to an obese subject an amount effective of pyridoxamine to treat or inhibit obesity-related complications selected from the group consisting of hyperlipidemia, renal disease, proliferation or smooth muscle cells in the aorta, coronary artery occlusion, atherosclerosis, hypertension, advanced glycation end-product formation and advanced lipoxidation end-product formation.
AU2002218002A 2000-11-02 2001-11-02 Use of pyridoxamine for the treatment and inhibition of obesity-related complications Abandoned AU2002218002A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24563000P 2000-11-02 2000-11-02
US60/245,630 2000-11-02
US31578901P 2001-08-29 2001-08-29
US60/315,789 2001-08-29
PCT/US2001/045415 WO2002036109A2 (en) 2000-11-02 2001-11-02 Use of pyridoxamine for the treatment and inhibition of obesity-related complications

Publications (1)

Publication Number Publication Date
AU2002218002A1 true AU2002218002A1 (en) 2002-05-15

Family

ID=26937355

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002218002A Abandoned AU2002218002A1 (en) 2000-11-02 2001-11-02 Use of pyridoxamine for the treatment and inhibition of obesity-related complications

Country Status (6)

Country Link
US (1) US20020128295A1 (en)
EP (1) EP1341532B1 (en)
AT (1) ATE333868T1 (en)
AU (1) AU2002218002A1 (en)
DE (1) DE60121794D1 (en)
WO (1) WO2002036109A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030146B2 (en) * 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
DK1643999T3 (en) * 2003-06-20 2012-01-02 Nephrogenex Inc Pyridoxamine for use in the treatment of diabetic nephropathy in type 2 diabetes
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
US7214799B2 (en) * 2004-02-09 2007-05-08 Biostratum, Inc. Methods for the synthesis of pyridoxamine
CN100558359C (en) * 2004-09-06 2009-11-11 兴和株式会社 Remedy for glomerular diseae
DE102004050353A1 (en) * 2004-10-15 2006-04-20 Basf Ag Use of stable ammonium salts of lipoic acid for the treatment of diabetic and other disorders
CA2844150C (en) 2011-07-12 2019-09-03 Vanderbilt University Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
BR112019022523A2 (en) 2017-04-27 2020-05-12 Vanderbilt University METHODS FOR TREATING AEROSCLEROSIS WITH GETO-KETOALDEHYDE SEQUESTRANTS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288716A (en) * 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
US6228858B1 (en) * 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
WO2000021516A2 (en) * 1998-10-14 2000-04-20 Kansas University Medical Center Research Institute, Inc. Methods for inhibiting diabetic complications
ES2197689T3 (en) * 1998-10-22 2004-01-01 University Of South Carolina PROCEDURES TO INHIBIT DIABETIC COMPLICATIONS.

Also Published As

Publication number Publication date
WO2002036109A3 (en) 2003-05-30
US20020128295A1 (en) 2002-09-12
EP1341532A2 (en) 2003-09-10
EP1341532B1 (en) 2006-07-26
DE60121794D1 (en) 2006-09-07
ATE333868T1 (en) 2006-08-15
WO2002036109A2 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
TW200512016A (en) Drug-coated stents and methods of use therefor
WO2002058684A3 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
ATE430568T1 (en) METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING ATHEROSCLERosis, RESTENOSIS AND RELATED DISEASES
WO2002100433A1 (en) Medicinal compositions
CA2380904A1 (en) Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
NO995718L (en) Herbal extract composition and method of innum "boosting" ability
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
EP1140840A4 (en) -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
DE69317578D1 (en) USE OF RILUZOLE FOR TREATING TRAUMATIC NEUROLOGICAL DAMAGES
DK0768885T3 (en) Method of inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
MX9705296A (en) Novel compounds.
MY127898A (en) Dual-release compositions of a cyclooxygenase-2 inhibitor
WO2001087306A8 (en) Compositions and methods for the treatment of colorectal cancer
DE69738667D1 (en) PREVENTATION AND TREATMENT OF COLONADOMENO OR COLONMICROADENOMA WITH 6-FLUORO-SODEOXYCHOLIC ACID
DE69526937D1 (en) USE OF METHANBISPHOSPHONIC ACID DERIVATIVES FOR TREATING LOSSED PROSTHESES
AU2002218002A1 (en) Use of pyridoxamine for the treatment and inhibition of obesity-related complications
MX9606503A (en) Pla2 inhibitors and their use for inhibition of intestinal cholesterol absorption.
NZ304291A (en) Trisubstituted phenyl derivatives, preparation and pharmaceutical compositions thereof
BG101875A (en) New cryptoficins and method for their preparation
NZ332096A (en) Alpha-hydroxylic acid derivatives their production and use in treating conditions requiring endothelin inhibition
AU8736798A (en) Use of cholinesterase inhibitors for treating attention deficit disorders
NO20000446D0 (en) Use of physiologically acceptable vanadium compounds, salts and complexes
WO2005089365A3 (en) Treatment and prevention of abnormal cellular proliferation
AU8020698A (en) Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain